Journal profile · HEMATOLOGY
Therapeutic Advances in Hematology
ISSN 2040-6207 · eISSN 2040-6215 · SAGE PUBLICATIONS LTD · United States
Therapeutic Advances in Hematology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 2.71; fully open access; APC about USD 2,650; median 171 days to acceptance (99 articles, last 24 months); acceptance rate 19.1% (journal website); 62 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Therapeutic Advances in Hematology is published by SAGE PUBLICATIONS LTD and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lymphoma Diagnosis and Treatment, Acute Myeloid Leukemia Research and Chronic Lymphocytic Leukemia Research, together about 27.6% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Therapeutic Advances in Hematology (TAH) is a peer-reviewed open access journal which has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in hematology. View full journal description This journal is a member of the Committee on Publication Ethics (COPE).
From the journal's Aims & Scope
Research area (LetPub): HEMATOLOGY
Editor-in-chief Elisabetta AbruzzesePublisher website
Editorial board by country: 3 in mainland China (about 4%); most named United States 35, United Kingdom 6, Germany 6, Italy 6, Mainland China 3 (82 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lymphoma Diagnosis and TreatmentMedicine10.4%
- Acute Myeloid Leukemia ResearchMedicine10%
- Chronic Lymphocytic Leukemia ResearchMedicine7.2%
- Multiple Myeloma Research and TreatmentsMedicine7%
- CAR-T cell therapy researchMedicine5.9%
- Myeloproliferative Neoplasms: Diagnosis and TreatmentMedicine5.9%
- Hematopoietic Stem Cell TransplantationMedicine5.8%
- Platelet Disorders and TreatmentsMedicine5.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Hematology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Hematology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Hematology | Zone 3 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.71LetPub ·
- Impact factor (publisher)
- 2.8Publisher website ·
- 5-year impact factor (publisher)
- 2.9Publisher website ·
- CiteScore 2026-06
- 5.3LetPub ·
- SJR 2026-06
- 1.02LetPub ·
- SNIP 2026-06
- 0.83LetPub ·
- h-index
- 56OpenAlex ·
- i10-index
- 351OpenAlex ·
- 2-year mean citedness
- 2.15OpenAlex ·
- Self-citation rate
- 3.6%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 58LetPub ·
- Articles per year (publisher)
- 3Publisher website ·
Articles by year OpenAlex count · 717 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 83 | 83 | 24 |
| 2025 | 62 | 62 | 115 |
| 2024 | 65 | 65 | 312 |
| 2023 | 51 | 51 | 511 |
| 2022 | 60 | 60 | 977 |
| 2021 | 65 | 65 | 1,071 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
171 daysMedian, submission to acceptance · P25–P75 131 days – 234 days
- Acceptance to online
- median 56 days (98 articles)
- Submission to online
- median 244 days
- Sample
- 99 articles with submission and acceptance dates (162 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 7 weeksLetPub ·
- Acceptance rate (publisher)
- 19.1%Publisher website ·
- Submission to first decision
- 9 daysPublisher website ·
- Acceptance to publication
- 43 daysPublisher website ·
- Submission to publication (journal-reported)
- about 7 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,650 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,650 | — | — | |
| LetPub | USD 2,650 | Yes | — | |
| Publisher website | USD 3,200 / USD 5,500 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare1 items from the author guidelines
- Reference style
- Vancouver
Article types accepted8
- original articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- original articlesOriginal Articles. The Editors will consider clinical interventional and observational studies with clearly stated aims, well-reported methodology (including ma…Length not stated
- perspectiveView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- reviewView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- review articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- review articlesReview Articles. These manuscripts are usually commissioned by the Editors but unsolicited reviews will be considered.Length not stated
- systematic reviewView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- systematic reviewsSystematic Reviews. these should answer a specific research question and involve a comprehensive search strategy aimed at identifying, assessing and summarisinLength not stated
Policy excerpts from the journal's websiteAuthorship, Data availability, Publication ethics, Open access, Peer review, Plagiarism, Preprints, Trial registration / reporting guidelines
- Authorship Author contributions
As part of our commitment to ensuring an ethical, transparent and fair peer review and publication process, this journal has adopted CRediT (Contributor Roles Taxonomy). CRediT is a high-level taxonomy, including 14 roles, which is used to describe each author’s individual contributions to the work. You will be asked to list the contribution of each author as part of the submission process. Please…
Source ↗Publisher website ·- Data availability Data availability
Research data sharing policy Model summary
The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. Subject to appropriate ethical and legal considerations, authors are encouraged to: Share your research data in a relevant public data repository Include a data ava…
Source ↗Publisher website ·- Publication ethics Ethical considerations
Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…
Source ↗Publisher website ·- Open access Publishing fees and open access
Therapeutic Advances in Hematology is an open access, peer-reviewed journal. All accepted articles are made freely available online immediately upon publication, are published under a Creative Commons license, and hosted online in perpetuity. If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable to cover the cost of publishing, pa…
Source ↗Publisher website ·- Peer review Peer review policy
Single anonymized peer review Model summary
The following summary describes the peer review process for this journal: Identity transparency: Single-anonymized Reviewer interacts with: Editor Review information published: None Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk rejec…
Source ↗Publisher website ·- Plagiarism Plagiarism
The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.
Source ↗Publisher website ·- Preprints Preprints
The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical trial registration
The journal conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- SAGE PUBLICATIONS LTD
- Country or region
- United States
- Language
- English
- ISSN
- 2040-6207
- Electronic ISSN
- 2040-6215
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Therapeutic Advances in Hematology
What CAS zone is Therapeutic Advances in Hematology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Therapeutic Advances in Hematology is in Zone 3 of Medicine, and in Zone 3 of the minor category Hematology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Therapeutic Advances in Hematology?
The latest impact factor listed by LetPub is 2.71; CiteScore 5.3, h-index 56.
How long does peer review take at Therapeutic Advances in Hematology?
Based on the dates recorded on 99 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 171 days (interquartile range 131–234 days); authors report an average review time of about 7 weeks; the journal's website gives an acceptance rate of 19.1%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Therapeutic Advances in Hematology based?
Of the 82 board members whose country the journal's board page names, 3 (about 4%) are in mainland China; the countries named most often are United States (35), United Kingdom (6) and Germany (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Therapeutic Advances in Hematology?
According to LetPub and DOAJ records, Therapeutic Advances in Hematology is indexed in SCIE, Scopus and DOAJ.
Is Therapeutic Advances in Hematology open access, and what is the APC?
Therapeutic Advances in Hematology is a fully open-access journal. APC about USD 2,650.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .